Li TT, Wu YF, Liu FQ, He FL. Hepatic amyloidosis leading to hepatic venular occlusive disease and Budd-Chiari syndrome: A case report. World J Clin Cases 2019; 7(20): 3282-3288 [PMID: 31667180 DOI: 10.12998/wjcc.v7.i20.3282]
Corresponding Author of This Article
Fu-Liang He, MD, PhD, Doctor, Department of Interventional Therapy, Beijing Shijitan Hospital, Capital Medical University, The 9th Affiliated Hospital of Peking University, Tieyi Road, No. 10, Haidian District, Beijing 100038, China. hefuliangjiayuan@163.com
Research Domain of This Article
Medicine, Research & Experimental
Article-Type of This Article
Case Report
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Oct 26, 2019; 7(20): 3282-3288 Published online Oct 26, 2019. doi: 10.12998/wjcc.v7.i20.3282
Hepatic amyloidosis leading to hepatic venular occlusive disease and Budd-Chiari syndrome: A case report
Ting-Ting Li, Yi-Fan Wu, Fu-Quan Liu, Fu-Liang He
Ting-Ting Li, Yi-Fan Wu, Fu-Quan Liu, Fu-Liang He, Department of Interventional Therapy, Beijing Shijitan Hospital, Capital Medical University, The 9th Affiliated Hospital of Peking University, Beijing 100038, China
Author contributions: Li TT and Wu YF are co-first authors; Li TT and Wu YF drafted the first manuscript; He LF and Liu FQ designed the study.
Informed consent statement: Informed written consent was obtained from the patient.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Fu-Liang He, MD, PhD, Doctor, Department of Interventional Therapy, Beijing Shijitan Hospital, Capital Medical University, The 9th Affiliated Hospital of Peking University, Tieyi Road, No. 10, Haidian District, Beijing 100038, China. hefuliangjiayuan@163.com
Telephone: +86-10-63926269 Fax: +86-10-63925588
Received: May 17, 2019 Peer-review started: May 21, 2019 First decision: July 30, 2019 Revised: August 30, 2019 Accepted: September 9, 2019 Article in press: September 9, 2019 Published online: October 26, 2019 Processing time: 162 Days and 10.7 Hours
Abstract
BACKGROUND
Systemic amyloidosis in which multiple systems can be involved has become a common clinical disease. When the liver is affected, symptoms such as abdominal distension, fatigue, edema, liver, and jaundice could appear. To date, hepatic amyloidosis combined with hepatic venular occlusive disease and Budd-Chiari syndrome has not been reported.
CASE SUMMARY
A 54-year-old female patient was admitted to the Beijing Shijitan Hospital with hepatic amyloidosis leading to hepatic venular occlusion and Budd-Chiari syndrome in 2018. The patient underwent surgery 1 mo previously for liver rupture and hemorrhage after Budd-Chiari syndrome was diagnosed. She was diagnosed with hepatic venular occlusion, liver amyloidosis, and Budd-Chiari syndrome (i.e. extensive hepatic vein occlusion). Transjugular intrahepatic portosystem shunt was performed. After the treatment, the clinical symptoms improved markedly with increase in urine volume.
CONCLUSION
Hepatic amyloidosis with hepatic venous occlusion and Budd-Chiari syndrome is relatively rare clinically, and transjugular intrahepatic portosystem shunt is an effective treatment for this disease.
Core tip: Transjugular intrahepatic portosystem shunt is an effective treatment for hepatic amyloidosis with hepatic venous occlusion and Budd-Chiari syndrome.
